Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 420Lymphoma, Large B-Cell, Diffuse 93Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 79Recurrence 68Lymphoma 60Neoplasms, Plasma Cell 57Lymphoma, Mantle-Cell 56Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Lymphoma, B-Cell 24Neoplasms 23Myelodysplastic Syndromes 23Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 6Lenalidomide 4pomalidomide 3isatuximab 3Kidney Transplantation 3Calcium Dobesilate 3glucarpidase 2Thalidomide 2Paclitaxel 2Gemcitabine 2Carboplatin 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1gamma-Glutamyl Hydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Renal Insufficiency × Lenalidomide × Clear all
NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Emory University

Phase 2 Terminated
17 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01270932 2017-12-29

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

University Health Network, Toronto

Phase 2 Completed
28 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT00779922 2016-10-11

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Poitiers University Hospital

Phase 2 Completed
39 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon ⚡